黑色素瘤个体化治疗策略：基于新抗原的特异性免疫治疗

doi:10.3969/j.issn.1006-5725.2024.10.001

Abstract

Abstract:

Immune checkpoint inhibitors have significantly improved the prognosis of patients with melanoma， but primary and acquired resistance have led to a bottleneck in treatment. The binding of T-cell receptors to tumor antigens is the key point for immunotherapy. Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations. Neoantigens， identifiable as foreign entities， have the capacity to initiate an immune response unfettered by central and peripheral tolerance mechanisms. This distinctive characteristic renders them highly promising targets in the realm of cancer therapy. Vaccines targeting tumor neoantigens， adoptive cell transfer， and antibody-based therapies can effectively enhance and expand tumor-specific immune responses， promoting T-cell recognition and elimination of tumors， thereby breaking through current treatment bottlenecks. This article discusses the current status， recent advancements， clinical challenges， and future directions in the personalized treatment of melanoma based on neoantigens.

Key words: melanoma, neoantigen, immunotherapy

CLC Number:

R739.5

Xizhi WEN,Xiaoshi. ZHANG. Immunotherapy based on neoantigen： A personalized treatment strategy for melanoma[J]. The Journal of Practical Medicine, 2024, 40(10): 1331-1337.

References 61

1	CURTI B D， FARIES M B. Recent Advances in the Treatment of Melanoma［J］. N Engl J Med， 2021， 384（23）：2229-2240. doi:10.1056/nejmra2034861 doi: 10.1056/nejmra2034861
2	LARKIN J， CHIARION-SILENI V， GONZALEZ R， et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma［J］. N Engl J Med， 2019， 381（16）：1535-1546. doi:10.1056/nejmoa1910836 doi: 10.1056/nejmoa1910836
3	OLIVEIRA G， STROMHAUG K， KLAEGER S， et al. Phenotype， specificity and avidity of antitumour CD8（+） T cells in melanoma［J］. Nature， 2021， 596（7870）：119-125. doi:10.1038/s41586-021-03704-y doi: 10.1038/s41586-021-03704-y
4	KIM J M， CHEN D S. Immune escape to PD-L1/PD-1 blockade： seven steps to success （or failure）［J］. Ann Oncol， 2016， 27（8）：1492-1504. doi:10.1093/annonc/mdw217 doi: 10.1093/annonc/mdw217
5	VESELY M D， ZHANG T， CHEN L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy［J］. Annu Rev Immunol， 2022， 40：45-74. doi:10.1146/annurev-immunol-070621-030155 doi: 10.1146/annurev-immunol-070621-030155
6	DESAI R， COXON A T， DUNN G P. Therapeutic applications of the cancer immunoediting hypothesis［J］. Semin Cancer Biol， 2022， 78：63-77. doi:10.1016/j.semcancer.2021.03.002 doi: 10.1016/j.semcancer.2021.03.002
7	GHORANI E， SWANTON C， QUEZADA S A. Cancer cell-intrinsic mechanisms driving acquired immune tolerance［J］. Immunity， 2023， 56（10）：2270-2295. doi:10.1016/j.immuni.2023.09.004 doi: 10.1016/j.immuni.2023.09.004
8	SUN Q， HONG Z， ZHANG C， et al. Immune checkpoint therapy for solid tumours： clinical dilemmas and future trends［J］. Signal Transduct Target Ther， 2023， 8（1）：320. doi:10.1038/s41392-023-01522-4 doi: 10.1038/s41392-023-01522-4
9	CHANDRAN S S， KLEBANOFF C A. T cell receptor-based cancer immunotherapy： Emerging efficacy and pathways of resistance［J］. Immunol Rev， 2019， 290（1）：127-147. doi:10.1111/imr.12772 doi: 10.1111/imr.12772
10	SCHUMACHER T N， SCHREIBER R D. Neoantigens in cancer immunotherapy［J］. Science， 2015， 348（6230）：69-74. doi:10.1126/science.aaa4971 doi: 10.1126/science.aaa4971
11	WACH M M， SUBJECK J R， WANG X Y， et al. Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients［J］. Melanoma Res， 2022， 32（2）：88-97. doi:10.1097/cmr.0000000000000796 doi: 10.1097/cmr.0000000000000796
12	GORDY J T， LUO K， ZHANG H， et al. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model［J］. J Immunother Cancer， 2016， 4：96. doi:10.1186/s40425-016-0189-y doi: 10.1186/s40425-016-0189-y
13	YAN J， TINGEY C， LYDE R， et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model［J］. Cancer Gene Ther， 2014， 21（12）：507-517. doi:10.1038/cgt.2014.56 doi: 10.1038/cgt.2014.56
14	GROB J J， MORTIER L， D'HONDT L， et al. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma： an open phase I/II study with a first assessment of a predictive gene signature［J］. ESMO Open， 2017， 2（5）：e000203. doi:10.1136/esmoopen-2017-000203 doi: 10.1136/esmoopen-2017-000203
15	DRENO B， THOMPSON J F， SMITHERS B M， et al. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected， MAGE-A3-positive， stage Ⅲ melanoma （DERMA）： a double-blind， randomised， placebo-controlled， phase 3 trial［J］. Lancet Oncol， 2018， 19（7）：916-929. doi:10.1016/s1470-2045(18)30254-7 doi: 10.1016/s1470-2045(18)30254-7
16	SCHWARTZENTRUBER D J， LAWSON D H， RICHARDS J M， et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma［J］. N Engl J Med， 2011， 364（22）：2119-2127. doi:10.1056/nejmoa1012863 doi: 10.1056/nejmoa1012863
17	XIE N， SHEN G， GAO W， et al. Neoantigens： promising targets for cancer therapy［J］. Signal Transduct Target Ther， 2023， 8（1）：9. doi:10.1038/s41392-022-01270-x doi: 10.1038/s41392-022-01270-x
18	YARCHOAN M， JOHNSON B A 3rd， LUTZ E R， et al. Targeting neoantigens to augment antitumour immunity［J］. Nat Rev Cancer， 2017， 17（4）：209-222. doi:10.1038/nrc.2016.154 doi: 10.1038/nrc.2016.154
19	LI J， XIAO Z， WANG D， et al. The screening， identification， design and clinical application of tumor-specific neoantigens for TCR-T cells［J］. Mol Cancer， 2023， 22（1）：141. doi:10.1186/s12943-023-01844-5 doi: 10.1186/s12943-023-01844-5
20	PERI A， SALOMON N， WOLF Y， et al. The landscape of T cell antigens for cancer immunotherapy［J］. Nat Cancer， 2023， 4（7）：937-954. doi:10.1038/s43018-023-00588-x doi: 10.1038/s43018-023-00588-x
21	TURAJLIC S， LITCHFIELD K， XU H， et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype： a pan-cancer analysis［J］. Lancet Oncol， 2017， 18（8）：1009-1021. doi:10.1016/s1470-2045(17)30516-8 doi: 10.1016/s1470-2045(17)30516-8
22	TEIXIDO C， CASTILLO P， MARTINEZ-VILA C， et al. Molecular Markers and Targets in Melanoma［J］. Cells， 2021， 10（9）：2320. doi:10.3390/cells10092320 doi: 10.3390/cells10092320
23	YARCHOAN M， HOPKINS A， JAFFEE E M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition［J］. N Engl J Med， 2017， 377（25）：2500-2501. doi:10.1056/nejmc1713444 doi: 10.1056/nejmc1713444
24	GONZÁLEZ F E， GLEISNER A， FALCóN-BEAS F， et al. Tumor cell lysates as immunogenic sources for cancer vaccine design［J］. Hum Vaccin Immunother， 2014， 10（11）：3261-3269. doi:10.4161/21645515.2014.982996 doi: 10.4161/21645515.2014.982996
25	LIPSON E J， SHARFMAN W H， CHEN S， et al. Safety and immunologic correlates of Melanoma GVAX， a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting［J］. J Transl Med， 2015， 13：214. doi:10.1186/s12967-015-0572-3 doi: 10.1186/s12967-015-0572-3
26	KATSIKIS P D， ISHII K J， SCHLIEHE C. Challenges in developing personalized neoantigen cancer vaccines［J］. Nat Rev Immunol， 2024，24（3）：213-227. doi:10.1038/s41577-023-00937-y doi: 10.1038/s41577-023-00937-y
27	D'ALISE A M， SCARSELLI E. Getting personal in metastatic melanoma： neoantigen-based vaccines as a new therapeutic strategy［J］. Curr Opin Oncol， 2023， 35（2）：94-99. doi:10.1097/cco.0000000000000923 doi: 10.1097/cco.0000000000000923
28	BAFALOUKOS D， GAZOULI I， KOUTSERIMPAS C， et al. Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma： Future Prospects［J］. Vaccines （Basel）， 2023， 11（3）：636. doi:10.3390/vaccines11030636 doi: 10.3390/vaccines11030636
29	CARRENO B M， MAGRINI V， BECKER-HAPAK M， et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells［J］. Science， 2015， 348（6236）：803-808. doi:10.1126/science.aaa3828 doi: 10.1126/science.aaa3828
30	ROSENBERG S A， PACKARD B S， AEBERSOLD P M， et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report［J］. N Engl J Med， 1988， 319（25）：1676-1680. doi:10.1056/nejm198812223192527 doi: 10.1056/nejm198812223192527
31	ROSENBERG S A， YANG J C， SHERRY R M， et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy［J］. Clin Cancer Res， 2011， 17（13）：4550-4557. doi:10.1158/1078-0432.ccr-11-0116 doi: 10.1158/1078-0432.ccr-11-0116
32	HE J， XIONG X， YANG H， et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response［J］. Cell Res， 2022， 32（6）：530-542. doi:10.1038/s41422-022-00627-9 doi: 10.1038/s41422-022-00627-9
33	LI D， CHEN C， LI J， et al. A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8⁺ T cell therapy in patients with advanced solid tumors［J］. Nat Commun， 2023， 14（1）：3447. doi:10.1038/s41467-023-39225-7 doi: 10.1038/s41467-023-39225-7
34	MüLLER M， HUBER F， ARNAUD M， et al. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction［J］. Immunity， 2023， 56（11）：2650-2663.e6. doi:10.1016/j.immuni.2023.09.002 doi: 10.1016/j.immuni.2023.09.002
35	RICKER C A， MELI K， VAN ALLEN E M. Historical perspective and future directions： computational science in immuno-oncology［J］. J Immunother Cancer， 2024， 12（1）：e008306. doi:10.1136/jitc-2023-008306 doi: 10.1136/jitc-2023-008306
36	CHONG C， COUKOS G， BASSANI-STERNBERG M. Identification of tumor antigens with immunopeptidomics［J］. Nat Biotechnol， 2022， 40（2）：175-188. doi:10.1038/s41587-021-01038-8 doi: 10.1038/s41587-021-01038-8
37	HOENISCH GRAVEL N， NELDE A， BAUER J， et al. TOF（IMS） mass spectrometry-based immunopeptidomics refines tumor antigen identification［J］. Nat Commun， 2023， 14（1）：7472. doi:10.1038/s41467-023-42692-7 doi: 10.1038/s41467-023-42692-7
38	ROESLER A S， ANDERSON K S. Beyond Sequencing： Prioritizing and Delivering Neoantigens for Cancer Vaccines［J］. Methods Mol Biol， 2022， 2410：649-670. doi:10.1007/978-1-0716-1884-4_35 doi: 10.1007/978-1-0716-1884-4_35
39	MINEGISHI Y， HAGA Y， UEDA K. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy［J］. Cancer Sci， 2024. doi：10.1111/cas.16118 . doi: 10.1111/cas.16118
40	OTT P A， HU Z， KESKIN D B， et al. An immunogenic personal neoantigen vaccine for patients with melanoma［J］. Nature， 2017， 547（7662）：217-221. doi:10.1038/nature22991 doi: 10.1038/nature22991
41	SAHIN U， DERHOVANESSIAN E， MILLER M， et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer［J］. Nature， 2017， 547（7662）：222-226.
42	WEBER J S， CARLINO M S， KHATTAK A， et al. Individualised neoantigen therapy mRNA-4157 （V940） plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma （KEYNOTE-942）： a randomised， phase 2b study［J］. Lancet， 2024， 403（10427）：632-644. doi:10.1016/s0140-6736(23)02268-7 doi: 10.1016/s0140-6736(23)02268-7
43	VAN DEN BERG J H， HEEMSKERK B， VAN ROOIJ N， et al. Tumor infiltrating lymphocytes （TIL） therapy in metastatic melanoma： boosting of neoantigen-specific T cell reactivity and long-term follow-up［J］. J Immunother Cancer， 2020， 8（2）：e000848. doi:10.1136/jitc-2020-000848 doi: 10.1136/jitc-2020-000848
44	SARNAIK A A， HAMID O， KHUSHALANI N I， et al. Lifileucel， a Tumor-Infiltrating Lymphocyte Therapy， in Metastatic Melanoma［J］. J Clin Oncol， 2021， 39（24）：2656-2666. doi:10.1200/jco.21.00612 doi: 10.1200/jco.21.00612
45	ROHAAN M W， BORCH T H， VAN DEN BERG J H， et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma［J］. N Engl J Med， 2022， 387（23）：2113-2125.
46	CAUSHI J X， ZHANG J， JI Z， et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers［J］. Nature， 2021， 596（7870）：126-132. doi:10.1038/s41586-021-03752-4 doi: 10.1038/s41586-021-03752-4
47	KLEBANOFF C A， CHANDRAN S S， BAKER B M， et al. T cell receptor therapeutics： immunological targeting of the intracellular cancer proteome［J］. Nat Rev Drug Discov， 2023， 22（12）：996-1017. doi:10.1038/s41573-023-00809-z doi: 10.1038/s41573-023-00809-z
48	GROENEVELDT C， KINDERMAN P， VAN DEN WOLLENBERG D， et al. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy［J］. J Immunother Cancer， 2020， 8（2）：e001191. doi:10.1136/jitc-2020-001191 doi: 10.1136/jitc-2020-001191
49	GERBER H P， PRESTA L G. TCR mimic compounds for pHLA targeting with high potency modalities in oncology［J］. Front Oncol， 2022， 12：1027548. doi:10.3389/fonc.2022.1027548 doi: 10.3389/fonc.2022.1027548
50	HASSEL J C， PIPERNO-NEUMANN S， RUTKOWSKI P， et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma［J］. N Engl J Med， 2023， 389（24）：2256-2266. doi:10.1056/nejmoa2304753 doi: 10.1056/nejmoa2304753
51	SHEN Y， WEI X， JIN S， et al. TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation［J］. Asian J Pharm Sci， 2020， 15（6）：777-785. doi:10.1016/j.ajps.2020.01.002 doi: 10.1016/j.ajps.2020.01.002
52	DOUGLASS J， HSIUE E H， MOG B J， et al. Bispecific antibodies targeting mutant RAS neoantigens［J］. Sci Immunol， 2021， 6（57）：eabd5515. doi:10.1126/sciimmunol.abd5515 doi: 10.1126/sciimmunol.abd5515
53	HSIUE E H， WRIGHT K M， DOUGLASS J， et al. Targeting a neoantigen derived from a common TP53 mutation［J］. Science， 2021， 371（6533）：eabc8697. doi:10.1126/science.abc8697 doi: 10.1126/science.abc8697
54	SHI Y， JING B， XI R. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors［J］. Genome Biol， 2023， 24（1）：169. doi:10.1186/s13059-023-03005-9 doi: 10.1186/s13059-023-03005-9
55	HUANG F， LI J， WEN X， et al. Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy［J］. Sci Rep， 2022， 12（1）：9559. doi:10.1038/s41598-022-13391-y doi: 10.1038/s41598-022-13391-y
56	MENG W， SCHREIBER R D， LICHTI C F. Recent advances in immunopeptidomic-based tumor neoantigen discovery［J］. Adv Immunol， 2023， 160：1-36. doi:10.1016/bs.ai.2023.10.001 doi: 10.1016/bs.ai.2023.10.001
57	POOLE A， KARUPPIAH V， HARTT A， et al. Therapeutic high affinity T cell receptor targeting a KRAS（G12D） cancer neoantigen［J］. Nat Commun， 2022， 13（1）：5333. doi:10.1038/s41467-022-32811-1 doi: 10.1038/s41467-022-32811-1
58	CHANDRAN S S， MA J， KLATT M G， et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA［J］. Nat Med， 2022， 28（5）：946-957. doi:10.1038/s41591-022-01786-3 doi: 10.1038/s41591-022-01786-3
59	CROSBY E J， HARTMAN Z C， LYERLY H K. Beyond Neoantigens： Antigens Derived from Tumor Drivers as Cancer Vaccine Targets［J］. Clin Cancer Res， 2023， 29（17）：3256-3258. doi:10.1158/1078-0432.ccr-23-1244 doi: 10.1158/1078-0432.ccr-23-1244
60	ZHANG R， TANG L， WANG Y， et al. A Dendrimer Peptide （KK2DP7） Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy［J］. Adv Sci （Weinh）， 2023， 10（15）：e2300116. doi:10.1002/advs.202300116 doi: 10.1002/advs.202300116
61	PANT S， WAINBERG Z A， WEEKES C D， et al. Lymph-node-targeted， mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer： the phase 1 AMPLIFY-201 trial［J］. Nat Med， 2024， 30（2）：531-542. doi:10.1038/s41591-023-02760-3 doi: 10.1038/s41591-023-02760-3

[1]	Jiang SHAO,Lin LI,Yansong GUO,Chengyuan SUN,Xichao WEN,Kebin ZHENG,Yanfang SHI. Research progress of CD73/NT5E in glioblastoma [J]. The Journal of Practical Medicine, 2024, 40(3): 428-431.
[2]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[3]	Ziqi DING,Qian. ZHANG. Research progress in T cell exhaustion and its relationship with respiratory diseases [J]. The Journal of Practical Medicine, 2024, 40(13): 1895-1900.
[4]	Yawei ZHANG,Hongjin SHI,Shi FU,Jiansong WANG,Haifeng WANG. Research progress in biological role of TIGIT and its application in bladder cancer [J]. The Journal of Practical Medicine, 2024, 40(12): 1762-1766.
[5]	WU Kaiyi, LÜ Xuedong, HE Haiyan, CHEN Jinliang. . Progress in the application of cryoablation combined with immunotherapy in the treatment of NSCLC [J]. The Journal of Practical Medicine, 2023, 39(8): 1058-1062.
[6]	ZHANG Xijie, LI Xin, ZHOU Wence.. Research progress of combined immunotherapy for metastatic pancreas cancer [J]. The Journal of Practical Medicine, 2023, 39(6): 655-659.
[7]	CHEN Fukun, LV Juan, DENG Zhiyong. Effect of chimeric antigen receptor gene⁃modified T⁃cell immunotherapy for lung cancer：A systematic review [J]. The Journal of Practical Medicine, 2023, 39(5): 538-543.
[8]	WU Yang, LU Hanjie, SHUI Huifeng.. The efficacy and safety of anlotinib plus PD⁃1 blockades in patients with advanced non⁃small cell lung can⁃ cer previously treated with immunotherapy [J]. The Journal of Practical Medicine, 2023, 39(5): 572-578.
[9]	Xianlan ZHANG,Yufei ZHU,Yunyun ZENG,Zhihao HUANG,Wenchang CEN,Shan. SU. Efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating advanced non-small cell lung cancer [J]. The Journal of Practical Medicine, 2023, 39(16): 2112-2115.
[10]	TIAN Jing, ZHANG Zhiyong, BAI Tiankai, YAN Bin.. CAR ⁃T therapy for pancreatic cancer：Research progress and prospects [J]. The Journal of Practical Medicine, 2022, 38(4): 516-521.
[11]	XU Lu, HUANG Liyou, WANG Yanhua, WEN Linchun.. Efficacy and safety ofPD ⁃ 1 inhibitor combined with brain radiotherapy for brain metastases in patients with pan⁃negative non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2022, 38(24): 3100-3105.
[12]	PENG Sijing, LU Jielun, WANG Zicheng, ZENG Xiaozhen, ZOU Yawei.. A progress on immunotherapy for childhood acute lymphoblastic leukemia [J]. The Journal of Practical Medicine, 2022, 38(23): 2903-2907.
[13]	SHI Fujun. Research progresses of breast cancer vaccines for breast cancer [J]. The Journal of Practical Medicine, 2022, 38(20): 2505-2509.
[14]	ZHANG Ying, WU Yueling.. Immunotherapy incervical cancer：The advent of precision medicine [J]. The Journal of Practical Medicine, 2022, 38(15): 1856-1859.
[15]	HE Jun, WU Songbai, LYU Ailian, DAI Yao, HUANG Kang, FANG Xiang, LYU Jianlei, LIU Min, ZHANG Quan, PENG Jing. Research on strategy of immunotherapy in elderly sepsis patients with immunosuppression [J]. The Journal of Practical Medicine, 2021, 37(6): 718-721.

Immunotherapy based on neoantigen： A personalized treatment strategy for melanoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 61

Related Articles 15

Recommended Articles

Metrics

Comments